Cargando…

The Emerging Role of NK Cells in Immune Checkpoint Blockade

Detalles Bibliográficos
Autores principales:	Martinez-Perez, Alejandra, Aguilar-Garcia, Candelaria, Gonzalez, Segundo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9736655/ https://www.ncbi.nlm.nih.gov/pubmed/36497486 http://dx.doi.org/10.3390/cancers14236005

Ejemplares similares

Corticosteroids and immune checkpoint blockade
por: Min, Le, et al.
Publicado: (2015)

Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer
por: Macherla, Shravanti, et al.
Publicado: (2018)

Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer
por: Riess, Jonathan W., et al.
Publicado: (2016)

Cancer Mutational Load: The More the Merrier for Immune Checkpoint Blockade Therapies
Publicado: (2016)

Systemic immunological biomarkers of clinical responses in immune checkpoint blockade therapies
por: Arasanz, Hugo, et al.
Publicado: (2018)

LIGHTing tumor up for checkpoint blockade
por: Liang, Yong, et al.
Publicado: (2016)

The role of neoantigen in immune checkpoint blockade therapy
por: Yi, Ming, et al.
Publicado: (2018)

The Role of Immune Checkpoint Blockade in Uveal Melanoma
por: Wessely, Anja, et al.
Publicado: (2020)

Harnessing radiotherapy-induced NK-cell activity by combining DNA damage–response inhibition and immune checkpoint blockade
por: Patin, Emmanuel C, et al.
Publicado: (2022)

Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human solid tumors
por: Li, Yangyang, et al.
Publicado: (2021)

The negative NK cell maturation checkpoint Foxo1
por: Deng, Youcai, et al.
Publicado: (2015)

Inhibiting the inhibitors: Checkpoints blockade in solid tumors
por: Mavilio, Domenico, et al.
Publicado: (2013)

HSP90 as an emerging barrier to immune checkpoint blockade therapy
por: Tang, Daolin, et al.
Publicado: (2022)

NK Cell-Based Immune Checkpoint Inhibition
por: Khan, Muhammad, et al.
Publicado: (2020)

Immune checkpoint blockade in HIV
por: Gubser, Celine, et al.
Publicado: (2022)

Rethinking immune checkpoint blockade: ‘Beyond the T cell’
por: Liu, Xiuting, et al.
Publicado: (2021)

Immune Checkpoint Blockade in Gastrointestinal Cancers: The Current Status and Emerging Paradigms
por: Miljanic, Mihailo, et al.
Publicado: (2020)

Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
por: Roy, Dia, et al.
Publicado: (2023)

Immunoglobulin‐like transcript 2 blockade restores antitumor immune responses in glioblastoma
por: Lorenzo‐Herrero, Seila, et al.
Publicado: (2022)

Control of NK Cell Activation by Immune Checkpoint Molecules
por: Beldi-Ferchiou, Asma, et al.
Publicado: (2017)

An unsuspected complication with immune checkpoint blockade: a case report
por: Carril-Ajuria, Lucia, et al.
Publicado: (2018)

Is there a role for immune checkpoint blockade in metastatic uveal melanoma?
por: Schilling, Bastian, et al.
Publicado: (2015)

Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?
por: Cha, Edward, et al.
Publicado: (2013)

Immune checkpoint blockade in ovarian cancer
por: Weiss, Lukas, et al.
Publicado: (2016)

Hallmarks of response to immune checkpoint blockade
por: Cogdill, Alexandria P, et al.
Publicado: (2017)

Immune-Checkpoint Blockade Therapy in Lymphoma
por: Kuzume, Ayumi, et al.
Publicado: (2020)

Activation of phagocytosis by immune checkpoint blockade
por: Li, Chia-Wei, et al.
Publicado: (2018)

Neutrophils in the era of immune checkpoint blockade
por: Faget, Julien, et al.
Publicado: (2021)

Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade
por: Saha, Dipongkor, et al.
Publicado: (2017)

Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia
por: Villa-Álvarez, Mónica, et al.
Publicado: (2018)

MCT4 blockade increases the efficacy of immune checkpoint blockade
por: Babl, Nathalie, et al.
Publicado: (2023)

Emerging role of SWI/SNF complex deficiency as a target of immune checkpoint blockade in human cancers
por: Zhou, Min, et al.
Publicado: (2021)

Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade
por: Peranzoni, Elisa, et al.
Publicado: (2020)

Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2023)

The SIRPα–CD47 immune checkpoint in NK cells
por: Deuse, Tobias, et al.
Publicado: (2021)

Advances in the management of gastrointestinal cancers—an upcoming role of immune checkpoint blockade
por: Goel, Gaurav, et al.
Publicado: (2015)

Role of tumor gene mutations in treatment response to immune checkpoint blockades
por: Wang, Manni, et al.
Publicado: (2019)

The role of IFN-γ-signalling in response to immune checkpoint blockade therapy
por: Wong, Chun Wai, et al.
Publicado: (2023)

Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockade
por: Wang, Chensu, et al.
Publicado: (2021)

Immune Checkpoint Blockade for the Treatment of Hodgkin Lymphoma
por: Lin, Adam Yuh, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_aea1j851me4glehatvi2objas4